ResMed Inc (ASX: RMD) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
ResMed Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$49.27 billion
P/E Ratio
24.77
Dividend Yield
0.93%
Shares Outstanding
1.47 billion
Earnings per share
0.847
Dividend per share
0.33
Year To Date Return
-6.73%
Earnings Yield
4.04%
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...
See The 5 Stocks *Returns as of 3 April 2025
ResMed Inc (ASX: RMD)
Latest News
How to invest
The power of compounding: What $1,000 a month in ASX shares could become
How to invest
How to build a winning $250,000 ASX share portfolio starting from zero
How to invest
5 Warren Buffett quotes to become a better ASX share investor
Healthcare Shares
3 of the best ASX 200 healthcare shares to bring your portfolio to life
Broker Notes
5 top ASX 200 stocks that brokers rate as buys after the market selloff
How to invest
The ASX is on sale! Here's how I'd build a portfolio for the next decade
Growth Shares
How ASX growth shares could help you retire rich
Growth Shares
Why I'd buy these 3 ASX shares and not look back for 10 years
How to invest
How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility
How to invest
What I'd buy if I wanted to turn $10,000 into $100,000 with ASX shares
Growth Shares
3 ASX 200 stocks I'd buy and hold for the next 10 years
Blue Chip Shares
3 quality ASX shares to buy before the market rebounds
Frequently Asked Questions
-
Yes. As well as being listed on the ASX since November 1999, ResMed trades on the New York Stock Exchange under the ticker code NYSE: RMD.
-
Yes, historically ResMed pays unfranked quarterly dividends each year. It does not offer a dividend reinvestment plan.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 12 Feb 2025 | $0.0581 | 0.00% | Interim | 20 Mar 2025 |
| 06 Nov 2024 | $0.0555 | 0.00% | Interim | 12 Dec 2024 |
| 14 Aug 2024 | $0.0561 | 0.00% | Final | 19 Sep 2024 |
| 08 May 2024 | $0.0508 | 0.00% | Interim | 13 Jun 2024 |
| 07 Feb 2024 | $0.0517 | 0.00% | Interim | 14 Mar 2024 |
| 08 Nov 2023 | $0.0528 | 0.00% | Interim | 14 Dec 2023 |
| 16 Aug 2023 | $0.0524 | 0.00% | Final | 21 Sep 2023 |
| 10 May 2023 | $0.0460 | 0.00% | Interim | 15 Jun 2023 |
| 08 Feb 2023 | $0.0444 | 0.00% | Interim | 16 Mar 2023 |
| 09 Nov 2022 | $0.0466 | 0.00% | Interim | 15 Dec 2022 |
| 17 Aug 2022 | $0.0445 | 0.00% | Final | 22 Sep 2022 |
| 11 May 2022 | $0.0429 | 0.00% | Interim | 16 Jun 2022 |
| 09 Feb 2022 | $0.0410 | 0.00% | Interim | 17 Mar 2022 |
| 10 Nov 2021 | $0.0403 | 0.00% | Interim | 16 Dec 2021 |
| 18 Aug 2021 | $0.0412 | 0.00% | Final | 23 Sep 2021 |
| 12 May 2021 | $0.0354 | 0.00% | Interim | 17 Jun 2021 |
| 10 Feb 2021 | $0.0352 | 0.00% | Interim | 18 Mar 2021 |
| 11 Nov 2020 | $0.0378 | 0.00% | Interim | 17 Dec 2020 |
| 19 Aug 2020 | $0.0379 | 0.00% | Final | 24 Sep 2020 |
| 13 May 2020 | $0.0423 | 0.00% | Interim | 18 Jun 2020 |
| 12 Feb 2020 | $0.0406 | 0.00% | Interim | 19 Mar 2020 |
| 06 Nov 2019 | $0.0396 | 0.00% | Interim | 12 Dec 2019 |
| 14 Aug 2019 | $0.0403 | 0.00% | Final | 19 Sep 2019 |
| 08 May 2019 | $0.0371 | 0.00% | Interim | 13 Jun 2019 |
| 06 Feb 2019 | $0.0365 | 0.00% | Interim | 14 Mar 2019 |
| 07 Nov 2018 | $0.0356 | 0.00% | Interim | 13 Dec 2018 |
| 15 Aug 2018 | $0.0357 | 0.00% | Final | 20 Sep 2018 |
| 09 May 2018 | $0.0326 | 0.00% | Interim | 14 Jun 2018 |
| 07 Feb 2018 | $0.0315 | 0.00% | Interim | 15 Mar 2018 |
| 08 Nov 2017 | $0.0320 | 0.00% | Interim | 14 Dec 2017 |
| 16 Aug 2017 | $0.0308 | 0.00% | Final | 21 Sep 2017 |
| 10 May 2017 | $0.0313 | 0.00% | Interim | 15 Jun 2017 |
| 08 Feb 2017 | $0.0303 | 0.00% | Interim | 16 Mar 2017 |
| 09 Nov 2016 | $0.0303 | 0.00% | Interim | 15 Dec 2016 |
| 17 Aug 2016 | $0.0300 | 0.00% | Final | 22 Sep 2016 |
| 18 May 2016 | $0.0291 | 0.00% | Interim | 16 Jun 2016 |
| 09 Feb 2016 | $0.0295 | 0.00% | Interim | 17 Mar 2016 |
| 17 Nov 2015 | $0.0292 | 0.00% | Interim | 17 Dec 2015 |
RMD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About ResMed Inc
ResMed Inc (ASX: RMD) is a global leader in sleep technology. It develops, manufactures, and distributes medical devices – such as flow generators, CPAP masks, and accessories – and cloud-based software applications that diagnose, treat, and manage a range of respiratory disorders including sleep apnea, chronic obstructive pulmonary disease (COPD), and neuromuscular disease.
It also provides software platforms to support professionals and caregivers to help patients in an out-of-hospital setting. The company operates in more than 140 countries, with manufacturing facilities in Australia, Singapore, France, and the United States. ResMed was established in Australia in 1989 but is now based in San Diego in the United States.
RMD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 14 Apr 2025 | $33.61 | $-0.60 | -1.75% | 1,733,756 | $33.84 | $34.04 | $33.44 |
| 11 Apr 2025 | $34.21 | $-0.62 | -1.78% | 1,354,760 | $33.63 | $34.36 | $33.22 |
| 10 Apr 2025 | $34.83 | $0.48 | 1.40% | 1,605,461 | $35.87 | $35.87 | $34.72 |
| 09 Apr 2025 | $34.35 | $-0.57 | -1.63% | 3,081,494 | $33.66 | $34.58 | $33.66 |
| 08 Apr 2025 | $34.92 | $1.46 | 4.36% | 2,012,742 | $35.74 | $35.80 | $34.85 |
| 07 Apr 2025 | $33.46 | $-0.40 | -1.18% | 4,155,863 | $32.17 | $34.00 | $32.04 |
| 04 Apr 2025 | $33.86 | $-0.92 | -2.65% | 3,508,477 | $33.78 | $34.18 | $33.50 |
| 03 Apr 2025 | $34.78 | $-0.48 | -1.36% | 971,900 | $34.95 | $34.95 | $34.64 |
| 02 Apr 2025 | $35.26 | $-0.37 | -1.04% | 637,371 | $35.21 | $35.61 | $35.15 |
| 01 Apr 2025 | $35.63 | $0.67 | 1.92% | 1,051,892 | $35.66 | $35.95 | $35.50 |
| 31 Mar 2025 | $34.96 | $-0.34 | -0.96% | 941,498 | $34.93 | $35.20 | $34.85 |
| 28 Mar 2025 | $35.30 | $-0.13 | -0.37% | 646,134 | $35.10 | $35.33 | $34.96 |
| 27 Mar 2025 | $35.43 | $0.03 | 0.08% | 627,226 | $35.30 | $35.51 | $35.15 |
| 26 Mar 2025 | $35.40 | $0.01 | 0.03% | 1,748,971 | $35.22 | $35.40 | $35.08 |
| 25 Mar 2025 | $35.39 | $0.51 | 1.46% | 1,389,531 | $35.31 | $35.47 | $35.22 |
| 24 Mar 2025 | $34.88 | $-0.24 | -0.68% | 1,036,515 | $35.20 | $35.30 | $34.86 |
| 21 Mar 2025 | $35.12 | $-0.14 | -0.40% | 1,217,060 | $35.20 | $35.20 | $34.80 |
| 20 Mar 2025 | $35.26 | $0.72 | 2.08% | 2,269,744 | $34.89 | $35.56 | $34.85 |
| 19 Mar 2025 | $34.54 | $-0.20 | -0.58% | 1,348,586 | $34.60 | $34.71 | $34.49 |
| 18 Mar 2025 | $34.74 | $-0.11 | -0.32% | 1,159,134 | $35.24 | $35.24 | $34.67 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Jul 2024 | Christopher Roberts | Issued | 12,000 | $611,400 |
Issue of options. https://www.aspecthuntley.com.au/asxdata/20040709/pdf/00445695.pdf, usd$
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Peter Craig Farrell | Non-Executive DirectorNon-Executive Chairman | Jul 2002 |
No profile reported in Annual Report.
|
| Mr Ronald R Taylor | Non-Executive Director | Jan 2005 |
Mr Taylor is a director of Actavis, Inc. and Red Lion Hotels Corp. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation. In 1987, Mr. Taylor founded Pyxis Corporation where he served as chairman, president, and chief executive officer until its purchase by Cardinal Health, Inc., in 1996.
|
| Mr Richard Sulpizio | Non-Executive Director | Aug 2005 |
Mr Sulpizio has served as president and chief executive officer of Qualcomm Enterprise Services. He currently serves as a senior advisor to Qualcomm Enterprise Services. Mr Sulpizio held various positions with Qualcomm during his 20-year tenure there, including president and chief operating officer. He served as a member of Qualcomm's board of directors from 2000 until 2007.
|
| Mr Michael J Farrell | Chief Executive OfficerExecutive Director | Mar 2013 |
Mr Farrell was foundation director of Biomedical Engineering at the University of New South Wales where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. Since 2005, Dr Farrell has been a director of NuVasive, Inc. He also serves as the non-executive chair of QRxPharma.
|
| Ms Carol Burt | Non-Executive Director | Aug 2014 |
No profile reported in Annual Report.
|
| Ms Karen Ruth Drexler | Non-Executive Director | Nov 2017 |
No profile reported in Annual Report.
|
| Mr Jan De Witte | Non-Executive Director | May 2019 |
Mr De Witte is the chief executive officer and member of the board of directors of Barco NV.
|
| Ms Harjit Gill | Non-Executive Director | Nov 2018 |
No profile reported in Annual Report.
|
| Mr John Hernandez | Non-Executive Director | Nov 2021 |
No profile reported in Annual Report.
|
| Mr Desney Tan | Non-Executive Director | Nov 2021 |
No profile reported in Annual Report.
|
| Mr Christopher DelOrefice | Non-Executive Director | Aug 2024 |
Mr DelOrefice, is the executive vice president and chief financial officer of Becton Dickinson and Company and has served in that role since September 2021. Previously, he served as Vice President, Investor Relations at Johnson & Johnson from August 2018 to September 2021 and Chief Financial Officer of North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018.
|
| Brett A. Sandercock | Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| N/A | 0 | 0.00% |